Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | Director | July 17, 2019 | July 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date July 17, 2019 · Filed July 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,640 |
Reported balance
After 2019-07-17 transaction · row 1
1 source rowRow 1 · 2019-07-17 · Grant · Acquired 7,057 · Balance 83,640 F1: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Corindus Vascular Robotics, Inc.
Report date October 29, 2019 · Filed October 31, 2019
Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 1
1 source rowRow 1 · 2019-10-29 · Disposition to issuer · Disposed 115,149 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: These shares represent 94,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2021-02-10 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-29 · Disposition to issuer · Disposed 50,004 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2021-02-10 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-29 · Disposition to issuer · Disposed 25,002 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2022-02-10 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-29 · Disposition to issuer · Disposed 57,504 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2022-02-10 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-10-29 · Disposition to issuer · Disposed 25,002 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2022-02-10 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-10-29 · Disposition to issuer · Disposed 25,002 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2025-05-27 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-10-29 · Disposition to issuer · Disposed 68,493 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2026-06-22 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-10-29 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2026-09-26 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-10-29 · Disposition to issuer · Disposed 27,272 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-10-29 · Disposition to issuer · Disposed 17,857 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: These shares represent 94,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes.
F4: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant.
F5: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes.
F6: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 17,857 | $2.60 Strike: $1.68 | $46,428.20 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 10 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,857 shares Expires 2027-06-21 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6 · derivative.exercise_date: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 27,272 | $3.18 Strike: $1.10 | $86,724.96 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 9 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,272 shares Expires 2026-09-26 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F6 · derivative.exercise_date: This option provided for vesting over a period of three years with 33.33% vesting on the first anniversary of issuance and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 35,000 | $2.82 Strike: $1.46 | $98,700.00 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 8 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2026-06-22 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 68,493 | $0.03 Strike: $4.25 | $2,054.79 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 7 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,493 shares Expires 2025-05-27 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 25,002 | $3.73 Strike: $0.55 | $93,257.46 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 6 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,002 shares Expires 2022-02-10 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 25,002 | $3.73 Strike: $0.55 | $93,257.46 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 5 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,002 shares Expires 2022-02-10 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 57,504 | $3.73 Strike: $0.55 | $214,489.92 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 4 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,504 shares Expires 2022-02-10 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 25,002 | $3.73 Strike: $0.55 | $93,257.46 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,002 shares Expires 2021-02-10 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerNon-qualified stock option (right to buy) · Derivative | 50,004 | $3.73 Strike: $0.55 | $186,514.92 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · derivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,004 shares Expires 2021-02-10 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F5 · price: At the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes. F4 · derivative.exercise_date: This option provided for vesting in two equal installments at the end of each anniversary of the date of grant. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 16:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | Disposition to issuerCommon Stock | 115,149 | $4.28 | $492,837.72 |
DisclosureSEC source: 0001387131-19-008132 · gold-form4_102919.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: These shares represent 94,412 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3 · price: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 21:20 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 7,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-015033 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,640 F1 · shares: The acquisition of 7,057 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,057 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/17/2020. Read SEC document |
| July 12, 2019 Filed Jul 18, 2019 16:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,650 | $0.00 Strike: $10.68 | $0.00 |
DisclosureSEC source: 0001567619-19-014985 · doc1.xml · derivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,650 shares Expires 2019-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for 25% of the shares each became exercisable on 08/07/2013, 08/07/2014, 08/07/2015 and 08/07/2016, respectively. Read SEC document |
| July 12, 2019 Filed Jul 18, 2019 16:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 3,276 | $21.68 | $71,023.68 |
DisclosureSEC source: 0001567619-19-014985 · doc1.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,583 Read SEC document |
| July 12, 2019 Filed Jul 18, 2019 16:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 6,650 | $10.68 | $71,022.00 |
DisclosureSEC source: 0001567619-19-014985 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2019 Filed May 7, 2019 18:35 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 27,649 | $2.17 | $59,998.33 |
DisclosureSEC source: 0001387131-19-003401 · gold-form4_050319.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,149 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units (RSUs) granted as part of the director's 2019 annual equity award. The RSUs provide for vesting in quarterly installments on August 3, 2019, November 3, 2019, February 3, 2020 and May 3, 2020, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. (Corindus) through each such vesting date. F2 · balance_after: Includes 53,326 shares of common stock related to RSUs granted as part of the director's 2018 annual equity award which provided for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 21:15 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 6,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033075 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,209 F1 · shares: The acquisition of 6,307 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,307 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/18/2019. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:44 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0001140361-18-032062 · doc1.xml · derivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2018-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for one-third of the shares became exercisable on 8/3/2012, 8/3/2013 and 8/3/2014, respectively. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:44 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 4,004 | $23.65 | $94,694.60 |
DisclosureSEC source: 0001140361-18-032062 · doc1.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,902 Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:44 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 7,000 | $13.53 | $94,710.00 |
DisclosureSEC source: 0001140361-18-032062 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:23 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0001140361-18-029784 · doc1.xml · derivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2018-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for one-third of the shares became exercisable on 8/3/2012, 8/3/2013 and 8/3/2014, respectively. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:23 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 4,228 | $22.40 | $94,707.20 |
DisclosureSEC source: 0001140361-18-029784 · doc1.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,906 Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:23 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 7,000 | $13.53 | $94,710.00 |
DisclosureSEC source: 0001140361-18-029784 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 18:03 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 53,326 | $0.75 | $39,999.83 |
DisclosureSEC source: 0001387131-18-002524 · gold-form4_053118.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units (RSUs) granted as part of the director's 2018 annual equity award. The RSUs provide for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31, 2019, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. (Corindus) through each such vesting date. F2 · balance_after: Includes 9,174 shares of common stock related to RSUs granted as part of the director's 2017 annual equity award which provided for initial vesting of one-quarter of the granted units and subsequent quarterly vesting on December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| May 16, 2018 Filed May 18, 2018 19:46 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | PurchaseCommon Stock | 15,000 | $0.80 | $12,000.00 |
DisclosureSEC source: 0001387131-18-002270 · gold-form4_051618.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,174 F1 · balance_after: Includes 9,174 shares of common stock related to restricted stock units granted as part of the director's annual equity award in 2017 which provided for initial vesting of one-quarter of the granted units and subsequent quarterly vesting on December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 20:17 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantRestricted Stock Units · Derivative | 9,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-17-005910 · gold-form4_121517.xml · derivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,174 Underlying: Common Stock · 9,174 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Corindus Vascular Robotics, Inc. F2 · derivative.exercise_date: The restricted stock units were granted on December 15, 2017 as part of the director's annual equity award with vesting beginning as of June 22, 2017, the date of the 2017 Annual Meeting of Stockholders. The restricted stock units vest in four equal quarterly installments on September 22, 2017, December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within five days of each such vesting date. F2 · derivative.expiration_date: The restricted stock units were granted on December 15, 2017 as part of the director's annual equity award with vesting beginning as of June 22, 2017, the date of the 2017 Annual Meeting of Stockholders. The restricted stock units vest in four equal quarterly installments on September 22, 2017, December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Vested shares will be delivered to the reporting person within five days of each such vesting date. Read SEC document |
| December 15, 2017 Filed Mar 6, 2018 19:01 UTC Amendment | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 9,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000941 · gold-form4a_121517.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,174 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award. The RSUs were initially vested with respect to one quarter of the granted units. The remaining quarterly installments will vest on December 22, 2017, March 22, 2018 and June 22, 2018, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 15:47 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 7,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-029123 · doc1.xml · nonDerivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,134 F1 · shares: The acquisition of 7,976 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,976 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/26/2018. Read SEC document |
| July 25, 2017 Filed Jul 28, 2017 15:47 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001140361-17-029123 · doc1.xml · derivative · entry 4 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2017-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options for 33 1/3% of the total number of shares each became exercisable on 8/3/2011, 8/3/2012 and 8/3/2013. Read SEC document |
| July 25, 2017 Filed Jul 28, 2017 15:47 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 12,879 | $17.12 | $220,488.48 |
DisclosureSEC source: 0001140361-17-029123 · doc1.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,158 Read SEC document |
| July 25, 2017 Filed Jul 28, 2017 15:47 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 14,000 | $15.75 | $220,500.00 |
DisclosureSEC source: 0001140361-17-029123 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:03 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantNon-qualified stock option (right to buy) · Derivative | 17,857 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001387131-17-003456 · gold-form4_062217.xml · derivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,857 Underlying: Common Stock · 17,857 shares Expires 2027-06-21 F1 · derivative.exercise_date: The underlying shares vest over a period of three years with 33.33% vesting on the first anniversary of the issuance date and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| November 25, 2016 Filed Nov 28, 2016 16:45 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | PurchaseCommon Stock | 902 | $0.76 | $685.52 |
DisclosureSEC source: 0001387131-16-008206 · gold-form4_112316.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 16:45 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | PurchaseCommon Stock | 9,098 | $0.76 | $6,914.48 |
DisclosureSEC source: 0001387131-16-008206 · gold-form4_112316.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,098 Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 17:34 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantNon-qualified stock option (right to buy) · Derivative | 27,272 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001387131-16-007138 · gold-form4_092716.xml · derivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,272 Underlying: Common Stock · 27,272 shares Expires 2026-09-26 F1 · derivative.exercise_date: Vesting start date is June 23, 2016. The options vest over a period of three years with 33.33% vesting on the first anniversary of the vesting date and 8.334% vesting at the end of each calendar quarter thereafter. Read SEC document |
| August 31, 2016 Filed Sep 6, 2016 18:51 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001140361-16-079003 · doc1.xml · derivative · entry 3 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2016-09-04 F1 · derivative.exercise_date: Options for one-third of the shares each became exercisable on 09/04/2010, 09/04/2011 and 09/04/2012, respectively. Read SEC document |
| August 31, 2016 Filed Sep 6, 2016 18:51 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Tax withholdingCommon Stock | 9,642 | $16.54 | $159,478.68 |
DisclosureSEC source: 0001140361-16-079003 · doc1.xml · nonDerivative · entry 2 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,037 Read SEC document |
| August 31, 2016 Filed Sep 6, 2016 18:51 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | Exercise / conversionCommon Stock | 12,000 | $13.29 | $159,480.00 |
DisclosureSEC source: 0001140361-16-079003 · doc1.xml · nonDerivative · entry 1 GOLD JEFFREY · CIK 0000938659 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.